

20th: Day 2

Session 5: Targeting signalling and mitosis

Chair *Jennie Mather*

- 2.25 pm Novel aspects of EGF-R-Directed Therapy.
Professor Thomas Valerius, Department of Nephrology, University of Schleswig-Holstein, Kiel, Germany.
- 2.45 pm Preclinical studies in the development of targeted anti-mitotics for cancer.
Professor, Ashok Venkitaraman, MRC Cancer Cell Unit, Cambridge, UK.
- 3.05 pm Modulation of DNA interactive therapy in cancer.
Dr. Daniel Hochhauser, UCL, London, UK.
- 3.25 pm Manipulating Protein-Protein interaction in cancer.
Dr. Terrence H. Rabbitts, MRC, Cambridge, UK.
- 3.45 pm Tea
- Session 6: Cancer Nanomedicine 1 – Targeted nanomaterials**
Chair *Kerry Chester*
- 4.15 pm Polymer Conjugates as Anticancer agents.
Professor Ruth Duncan, Cardiff University, Wales, UK.
- 4.35 pm Nanotechnology in the service of cancer Therapeutics and Diagnostics.
Dr. Kostas Kostarelos, Centre for the Drug Delivery, The School of Pharmacy, London, UK.
- 4.55 pm Challenges of Toxicity with nanomedicine.
Dr. S. Moein Moghimi, School of Pharmacy, University of Brighton, Brighton, UK.
- Session 7: Cancer Nanomedicine 2 – Using magnets**
Chair *Professor Ruth Duncan*
- 5.15 pm Applying Biomagnetics to Cancer Diagnostics and Therapy.
Professor Quentin Pankhurst, UCL, London, UK.
- 5.35 pm Targeting strategies for magnetic nanoparticles.
Jon Dobson, University of Keele, UK.
- 5.55 pm Recombinant antibody-targeted magnetic nanoparticles for cancer imaging and therapy.
Dr. Kerry Chester, UCL, London, UK.
- 6.15 pm Posters and networking
- 8.00 pm Gala dinner

21st: Day 3

- 9.00 am Novel therapeutic Mab/targets with Novel Mechanisms of Action
Dr. Jennie Mather, President, Founder and CSO, Raven Biotechnologies Inc., USA.
Chair *Paul W. H. I. Parren*
- Session 8: Harnessing or suppressing the immune response**
Chair *Mike Clark*
- 9.45 am Targeting the CD28/B7 Superfamily for Cancer Immunotherapy.
Dr. Nils Lonberg, Sr VP, Scientific Director, Medarex Inc, USA.
- 10.05 am Overcoming adverse immunity against therapeutic proteins for the treatment of cancer.
Dr. Matthew Baker, CEO and CSO, Antitope Ltd, Cambridge, UK.
- 10.25 am Reducing Immunogenicity of Therapeutic Proteins by modifying T-cell epitopes.
Dr. Duncan Wilkins, UCL London, UK.
- 10.45 am Coffee
- Session 9: Drug discovery and new frontiers.**
Chair *Dr. Jane Osbourn*
- 11.10 am The virtual patient for maximising efficacy/toxicity ratio of chemotherapy and biological drugs.
Professor Zavia Agur, President IMBM, Isreal.
- 11.30 am Oncology-focused Drug Discovery in collaboration with Academia.
Dr. Clive Stanway, Director Technology Development, CRT, London, UK.
- 11.50 am Bridging the Development Gap between Academia and Industry.
Dr. Keith Blundy, Chief Operating Officer, Director, CRT, London, UK.
- 12.10 pm Imaging and Cancer Management.
Dr. Leonard Fass, Director Academic Relations, GEHealthcare, UK.

Contact



Dr. G. Subramanian, 60b Jubilee Road,
Littlebourne, Canterbury,
Kent CT3 1TP U.K.

Tel: +44 (0) 7960 139108

Fax: +44 (0) 1227 722700

Email: gsub@subramanian.org.uk

Web: www.subramanian.org.uk

Produced by Hayward Design & Print • 01227 721864 • www.hayward-design.co.uk

WORLD BIOPHARM FORUM 2007

DEVELOPMENT OF NEW THERAPIES FOR CANCER



19 – 21 March, 2007

NEW HALL
CAMBRIDGE, UK

Please complete the registration form in BLOCK CAPITALS and **post** it with your remittance to:
Dr. G. Subramanian, 60b Jubilee Road, Littlebourne,
Canterbury, Kent, CT3 1TP, UK.

or email to gsub@subramanian.org.uk
to reserve your place which will be confirmed upon receipt of
your full payment.

Title (Prof. Dr. Mr. Mrs. Ms.):

Full Name:

Job Title:

Organisation:

Address:

.....

..... Postcode:

Country:

Tel:

Fax:

Email:

Any Special Requirement:

Registration fees:

Full attendance including all meals and gala dinner	£750
Attendance with no accommodation	£600
Day attendance for day one	£150
Day attendance for day two	£300
Day attendance for day three	£150

Method of payment:

Cheque payable to G. Subramanian in pound sterling only
and drawn on a UK based bank.

Cancellation

Should you be unable to attend, a substitute delegate is
welcomed at no extra charge. A charge of 50% of the
registration fee will be made for cancellation received in
writing before 25th February, 2007.

For marketing, exhibition and also poster presentation
contact: gsub@subramanian.org.uk or +44 (0) 7960 139108

SPONSOR



2.00 pm Welcome and Introduction

Dr. G. Subramanian

Session 1: Antibodies, drugs and natural effectors

Chair Ian Tomlinson

2.10 pm Human Antibody Therapeutics targeting CD20.

Dr. Paul W. H. I. Parren, VP, Genmab, The Netherlands.

2.30 pm Modes of Action of HuMax-EGFr: A fully Human Anti-EGF Receptor Monoclonal Antibody for Cancer Therapy.

Dr. Wim Bleeker, Genmab, The Netherlands.

2.50 pm Potent Antibody Drug Conjugates for Cancer Therapy

Dr. Paul Carter, VP, Antibody Technology, Seattle Genetics Inc., USA.

3.10 pm Altering effector cell and complement system recruitment through engineering antibody Fc regions.

Dr. Mike Clark, Department of Pathology, Cambridge University, UK.

3.30 pm Tea

Session 2: Antibody discovery and novel targeting agents

Chair Professor Agamemnon A. Epenetos

4.00 pm Application of Display Technologies to the Development of Biologic Drugs for Oncology.

Dr. Jane Osbourn, VP Drug Discovery Oncology, Cambridge Antibody Technologies, UK.

4.20 pm Targeting Tumour Vasculature.

Dr. Tim Meyer, UCL, London, UK.

4.40 pm Human Domain Antibodies as Novel Oncology Agents.

Dr. Ian Tomlinson, CSO, Domantis, Cambridge, UK.

5.00 pm Aptamers; A novel Cancer Therapeutics.

Dr. Nigel Courtenay-Luck, CSO, Antisoma, UK.

5.20 pm Small molecule and antibody therapeutics: alternative or complementary approaches to Cancer Therapy.

David Blakey, AstraZeneca, UK.

5.40 pm Posters and networking

6.30 pm Dinner

8.00 pm Keynote 1: Antibody Targeted Cancer Therapy.

*Professor Richard Begent, UCL, London, UK.
Chair Paul Carter*

Session 3: Cell based therapies

Chair Matthew Baker

9.00 am Stem Cells: Attacking the cancer's strength and turning it into its weakness.

Professor Agamemnon A. Epenetos, London, UK.

9.20 am Cell-Based Cancer Therapeutics.

Professor Robert Hawkins, Cancer Research UK, University of Manchester, Manchester, UK.

9.40 am Exploiting the potential of NK cells to kill tumour cells.

Dr. Melvyn Little, CSO and Deputy CEO, Affimed Therapeutics AG, Germany.

10.00 am OmniCyte – an adult bone marrow Stem Cell Progenator.

Professor Nagy A. Habib, Imperial College, London.

10.20 am Coffee

Session 4: Vaccines

Chair Robert Hawkins

10.50 am A Novel Therapeutic Vaccination Approach for Patients with Melanoma.

Dr. Neil Berinstein, Sanofi Pasteur, Toronto, Canada.

11.10 am Mechanisms of Melanoma regression after therapeutic vaccination with Mage Antigen.

Professor Pierre G. Coulie, Universite Catholique de Louvain, Brussels, Belgium.

11.30 am Therapeutic Vaccines coming to the scene.

Dr. Jean-Yves Bonnefoy, VP Research and Development, Transgene SA., France.

11.50 am Vaccine Strategies and combined Modalities for the Therapy of cancer.

Dr. James W. Hodge, Director Recombinant Vaccine Group, NIH, USA.

12.10 pm Lunch and posters

1.40 pm Keynote 2: P53 Tumour Suppressor: Structure, Function, Rescue.

*Professor Alan Fersht, Director, Centre for Protein Engineering, MRC, Cambridge, UK.
Chair Dr. Terrence H. Rabbitts*